Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage powerful synergistic biology. On an unprecedented scale, we are leading a fundamental change in the methods of discovery and engineering of multi-specific biologics. https://www.businesswire.com/news/home/20211014005033/en/Tentarix-Biotherapeutics-Emerges-with-50-Million-Series-A
| Website | http://www.tentarix.com |
| Revenue | $8.5 million |
| Employees | 56 (39 on RocketReach) |
| Founded | 2020 |
| Address | 10355 Science Center Dr Suite 120, San Diego, California 92121, US |
| Industry | Biotechnology, Drug Discovery |
| Keywords | Protein Therapeutics, Therapeutic Proteins, Biotherapeutics, Protein Engineering, Combination Therapies, Innovative Therapeutics, Therapeutic Antibodies, Innovative Medicines, Drug Discovery, Pharmaceutical Research, New Drug Development, Drug Development, Biotechnology, Biopharmaceutical, Biological Drugs, Pharmaceutical Development, Precision Medicine |
| Competitors | Johnson & Johnson, Roche, Novartis, Merck & Co., Inc., Pfizer, AstraZeneca, Bristol Myers Squibb, Genentech, Amgen, Lilly India +45 more (view full list) |
Looking for a particular Tentarix Biotherapeutics employee's phone or email?
The Tentarix Biotherapeutics annual revenue was $8.5 million in 2026.
Andy Kidd is the CEO of Tentarix Biotherapeutics.
39 people are employed at Tentarix Biotherapeutics.
Tentarix Biotherapeutics is based in San Diego, California.